The Group's principal activity is to develop, manufacture and market monoclonal antibody-based products for the detection and treatment of cancer, autoimmune and other serious diseases. The Group has developed a number of technologies to create humanized antibodies that can be either alone in unlabeled form, or conjugated with radioactive isotopes, chemotherapeutics or toxins to create highly targeted agents. The Group's product candidates and technologies are protected by a portfolio of intellectual property and it includes 137 issued patents in the United States and 300 other issued patents in the worldwide. The Group operates in the United States and Europe.
Alacra Alerts:
Receive alerts on the latest reports on Immunomedics, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
